Regeneron has announced new results from the phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its ...

AbbVie has announced results from the ongoing phase 3 Viti-Up-1 and Viti-Up-2 studies of Rinvoq (upadacitinib; 15mg once ...

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they ...

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, ...

The annual awards recognise excellence across 15 categories spanning innovation, manufacturing, sustainability and leadership ...

This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments ...

Chiesi UK and Ireland has announced a new programme to help transform COPD diagnosis across the UK by providing NHS primary ...

AstraZeneca has announced the opening of its newest global strategic research and development (R&D) centre, in Kendall Square ...

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment ...

Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator The Medicines and Healthcare products Regulatory Agency (MHRA) has approved KalVista ...

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic ...

Logistical challenges are not new in clinical research, from the high cost of developing new therapies to complexities in ...